225
0 Kommentare
NeuroPace Announces RNS System Enhancements Designed to Streamline Care - Seite 2
“We continue to focus on ease of use and scalability of our RNS System and the design and release of these enhancements demonstrates our commitment to enabling clinicians to more efficiently and effectively deliver patient care,” said Joel Becker, Chief Executive Officer of NeuroPace. “As we continue to focus on increased adoption of our RNS System and expanded utilization of our technology within the community setting, we believe it is critical to offer a product that is not only clinically superior, but also designed to facilitate streamlined care. I am proud of our team – from Product Development to Regulatory and Quality – as they work toward continuous improvement of the RNS System and, in turn, quality of life for patients,” continued Mr. Becker. “We are dedicated to delivering a product that is superior not only in outcomes, but also efficiency and ease of use.”
About NeuroPace, Inc.
Based in Mountain View, Calif., NeuroPace is a commercial-stage medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of
debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure
source. This platform can drive a better standard of care for patients living with drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the
large population of patients suffering from other brain disorders.
Lesen Sie auch
Forward Looking Statements
In addition to background and historical information, this press release contains “forward-looking statements” based on NeuroPace’s current expectations, forecasts and beliefs, including among
other things, the statements related to commercial strategy, execution, market expansion, operational performance, and growth, above. These forward-looking statements are subject to inherent
uncertainties, risks, and assumptions that are difficult to predict. Actual outcomes and results could differ materially due to a number of factors. These and other risks and uncertainties include
those described more fully in the section titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in NeuroPace’s public
filings with the U.S. Securities and Exchange Commission (SEC), including its Quarterly Report on Form 10-Q for the period ended June 30, 2023 filed with the SEC on August 08, 2023, as well as any
other reports that it may file with the SEC in the future. Forward-looking statements contained in this announcement are based on information available to NeuroPace as of the date hereof. NeuroPace
undertakes no obligation to update such information except as required under applicable law. These forward-looking statements should not be relied upon as representing NeuroPace’s views as of any
date subsequent to the date of this press release and should not be relied upon as a prediction of future events. In light of the foregoing, investors are urged not to rely on any forward-looking
statement in reaching any conclusion or making any investment decision about any securities of NeuroPace.